Yigitbasi Turkan, Calibasi-Kocal Gizem, Buyukuslu Nihal, Atahan Murat Kemal, Kupeli Hakan, Yigit Seyran, Tarcan Ercument, Baskin Yasemin
Department of Biochemistry, School of Medicine, Istanbul Medipol University, Istanbul 34810, Turkey.
Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.
Biomed Rep. 2018 Mar;8(3):269-274. doi: 10.3892/br.2018.1042. Epub 2018 Jan 15.
Breast cancer (BC) is the most frequently diagnosed cancer that affects women worldwide. Early detection of BC is important to improve survival rates and decrease mortality. The aim of the present study was to investigate serum biomarkers using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to distinguish patients with BC from the healthy population and patients with benign breast diseases (BBDs). A total of 62 patients with invasive ductal carcinoma, as confirmed by histopathology, and 47 non-cancerous individuals (NCIs) [16 healthy controls (HCs) and 31 patients with BBD] were enrolled in the present study. Serum protein profiles were determined by SELDI-TOF-MS using an immobilized metal affinity capture array. Serum from patients with BC were compared with that from the HC group using univariate and multivariate statistical analyses. A total of 118 clusters were generated from the individual serum. Univariate analysis revealed that 5 peaks were significantly downregulated (m/z 1,452, 2,670, 3,972, 5,354 and 5,523; P<0.001) and 4 were upregulated (m/z 6,850, 7,926, 8,115 and 8,143; P<0.001) in patients with BC compared with the HC group. A comparison of patients with BC and patients with BBD revealed an additional 9 protein peaks. Among these, 3 peaks (m/z 3,972, 5,336 and 11,185) were significantly downregulated and 6 peaks (m/z 4,062, 4,071, 4,609, 6,850, 8,115 and 8,133) were significantly upregulated. A total of 3 peaks [mass-to-change ratio (m/z) 3,972, 6,850 and 8,115 (BC2)] were common in both sets. The results of the present study suggest that a 4 protein peak set [m/z 3,972, 6,850 and 8,115 (BC2) and 8,949 (BC3)] could be used to distinguish patients with BC from NCI.
乳腺癌（BC）是全球女性中最常被诊断出的癌症。早期发现乳腺癌对于提高生存率和降低死亡率至关重要。本研究的目的是使用表面增强激光解吸电离飞行时间质谱（SELDI-TOF-MS）研究血清生物标志物，以区分乳腺癌患者与健康人群以及乳腺良性疾病（BBD）患者。本研究共纳入62例经组织病理学确诊的浸润性导管癌患者和47例非癌症个体（NCI）[16例健康对照（HC）和31例BBD患者]。使用固定化金属亲和捕获阵列通过SELDI-TOF-MS测定血清蛋白谱。采用单变量和多变量统计分析，将乳腺癌患者的血清与HC组的血清进行比较。从个体血清中共生成118个簇。单变量分析显示，与HC组相比，乳腺癌患者中有5个峰显著下调（m/z 1,452、2,670、3,972、5,354和5,523；P<0.001），4个峰上调（m/z 6,850、7,926、8,115和8,143；P<0.001）。乳腺癌患者与BBD患者的比较显示出另外9个蛋白峰。其中，3个峰（m/z 3,972、5,336和11,185）显著下调，6个峰（m/z 4,062、4,071、4,609、6,850、8,115和8,133）显著上调。两组共有3个峰[质荷比（m/z）3,972、6,850和8,115（BC2）]。本研究结果表明，一组4个蛋白峰[m/z 3,972、6,850和8,115（BC2）以及8,949（BC3）]可用于区分乳腺癌患者与NCI。
